This 2001 review analyzed long-term (≥36 weeks) placebo-controlled trials of obesity pharmacotherapy published since 1960. The study found that weight loss attributable to pharmacotherapy over 36–52 weeks was approximately 8.1% (7.9 kg) for phentermine resin, 5.0% (4.3 kg) for sibutramine, 3.4% (3.4 kg) for orlistat, and −1.5% (−1.5 kg) for
This 2013 review evaluates lorcaserin, a selective 5-HT₂C receptor agonist, for chronic weight management in obese and overweight adults. Clinical trials demonstrated that lorcaserin, as an adjunct to diet and exercise, led to significant weight loss compared to placebo. After 12 months, a higher proportion of lorcaserin-treated patients achieved ≥5%
This 2010 double-blind, randomized controlled trial (BLOOM) evaluated the efficacy and safety of lorcaserin, a selective 5-HT₂C receptor agonist, in 3,182 overweight or obese adults over 52 weeks. Participants received lorcaserin 10 mg twice daily or placebo, alongside lifestyle counseling. At 1 year, 47.5% of the lorcaserin group lost ≥5%
